Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology, probably
caused by a combination of genetic and environmental factors. The treatment of patients …

Abstract Background The Gemini trial failed to detect a significant difference in response rate
for patients with ulcerative colitis (UC) randomized to standard (every 8 week) vedolizumab …

Background Few data exist to help select a second biologic agent in patients with refractory
ulcerative colitis (UC). Aim To compare the efficacy of infliximab (IFX) and vedolizumab …

Background & Aims The efficacy and safety of vedolizumab, a humanized immunoglobulin
G1 monoclonal antibody against the integrin α4β7, were demonstrated in multicenter, phase …

Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor
necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A …

Background Prospectively designed studies assessing the exposure‐response profile of
vedolizumab are lacking. Observational exposure‐response data for vedolizumab are …

Background & Aims We created and validated a clinical decision support tool (CDST) to
predict outcomes of vedolizumab therapy for ulcerative colitis (UC). Methods We performed …

Background Biologic therapies are widely used in patients with ulcerative colitis. Head-to-
head trials of these therapies in patients with inflammatory bowel disease are lacking …

Background Vedolizumab, an anti‐α4β7 integrin monoclonal antibody (mA b), is indicated
for treating patients with moderately to severely active ulcerative colitis (UC) and Crohn's …

Abstract Background and Aims: The GEMINI long-term safety [LTS] study is a continuing
phase 3 trial investigating the safety and efficacy of vedolizumab, an α4β7 integrin …